Find a Clinical Trial
Researchers all over Australia and New Zealand are running clinical trials for people at different ages and stages of type 1 diabetes. Use our clinical trial finder below to find clinical trials near you.
Tailor your results by using the filters below
Hydroxychloroquine in Individuals At Risk for Type 1 Diabetes
This clinical trial is testing a medication called hydroxychloroquine (HCQ) to assess safety and effectiveness in people at risk of developing T1D. The study is enrolling people with T1D autoantibodies confirmed by screening, to see if HCQ can prevent T1D developing.
HCQ is used as a treatment for malaria, lupus, and rheumatoid arthritis. It has also been used extensively for treatment of autoimmune disease in adults, children, and during pregnancy. This medication has not previously been studied as a treatment to prevent T1D.
If you’re interested in taking part, contact Leanne or Felicity at email@example.com, or call 03 9342 7063.
Location NSW, QLD, SA, VIC, WA
Age 3+ years
Two or more T1D-related autoantibodies (confirmed by screening)
Normal oral glucose tolerance test results within 7 weeks of starting study
Trialling a New App to Help Manage Glucose Levels During Exercise (acT1ve)
The current exercise guidelines for T1D vary and are challenging to follow.
We have been working with young people with T1D, other researchers and app developers to create a new smartphone exercise app called acT1ve.
The app asks the user questions about the activity they are going to do, and based on this information, gives insulin and carbohydrate advice for the activity. The advice is based on international exercise guidelines. We have tested acT1ve with a small group of young people with T1D to see what they thought about it and would now like to trial it with a larger number of young people to use at home while being active.
Age 12-25 years
T1D diagnosis more than 6 months ago
Exercising regularly, or willing to start exercising
Own an iOS (Apple) or Android phone to use the app
Baricitinib in New Onset Type 1 Diabetes (BANDIT)
BANDIT is a clinical trial testing a drug called baricitinib that has the potential to slow or stop the destruction of beta cells in people with T1D.
Participants in the BANDIT trial must be between the ages of 12 – 30 years old, and must have been diagnosed with type 1 diabetes within the last 100 days.
Participants will be required to attend at one of four sites in Melbourne or Adelaide: The Royal Melbourne Hospital, The Royal Children’s Hospital, St Vincent’s Hospital Melbourne or the Women’s and Children’s Hospital Adelaide.
BANDIT has been approved by the Melbourne Health Human Research Ethics Committee (HREC).
ANZCTR listing: ACTRN12620000239965
INTIMET: Insulin Resistance in Type 1 Diabetes Managed with Metformin
Harmful patterns of insulin resistance in the muscle and liver may be an explanation for increased cardiovascular disease in T1D.
The INTIMET study is a detailed investigation of insulin resistance in T1D and will test if metformin can improve insulin action in muscle and the liver. Participants will be asked to take metformin (or placebo tablets) and are required to attend 4 appointments over 6 months at the Garvan Institute in Sydney.
This study is also recruiting people aged 20-50 without type 1 diabetes, who will attend 2 study visits but not receive medication.
ANZCTR listing: ANZCTR12619001440112
Age 20-50 years
T1D diagnosis more than 10 years ago
Cord Reinfusion in Diabetes (CORD) Pilot Study
Cell Care is partnering with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease.
The CORD study has been approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee.
ANZCTR listing: ACTRN12613000186752
Age 1-15 years
First- or second-degree relative with T1D
Children with stored cord blood, or parents expecting a child and planning cord blood storage
The Fenofibrate and Microvascular Events in Type 1 Diabetic Retinopathy (FAME-1-EYE) Study
This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D.
This study has been approved by the Northern Sydney Local Health District Human Research Ethics Committee.
ANZCTR listing: ACTRN12611000249954
Location NSW, SA, VIC, WA, New Zealand
Age 18+ years
Non-proliferative diabetic retinopathy (NPDR)
ETDRS score 35-53
Nox 1/4 Inhibition to Treat Kidney Disease in Type 1 Diabetes
This study is testing whether a new tablet can help to treat kidney disease in people with T1D. This tablet blocks a key component of the pathway responsible for the oxidative stress that damages kidneys. Participants in this clinical trial will attend 10 study visits over 56 weeks.
This study has been approved by the South Metropolitan Health Service Human Research Ethics Committee.
For more information or to take part, contact firstname.lastname@example.org.
Location NSW, VIC, SA, WA
Age 18-70 years
Albumin (protein) in the urine
Type1Screen: Screening for Type 1 Diabetes
Family members of people with T1D are at increased risk of developing the disease themselves.
Type1Screen is a free screening service available to any family member of a person with T1D, that can find out a person’s risk of developing T1D. Those at increased risk will be offered the opportunity to enrol in trials of new therapies that can potentially prevent T1D.
Location ACT, NSW, NT, QLD, SA, TAS, VIC, WA, New Zealand
Age 2-30 years
Have a relative diagnosed with T1D or have previously had a positive antibody test
Have access to a pathology collection centre
Advanced hybrid closed-loop technology for young people with T1D
Our researchers are looking for young people with type 1 diabetes with a HbA1c above 9% to be involved in a clinical trial of a new advanced hybrid closed-loop system.
We want to see if using the closed-loop insulin delivery system will improve time in range and HbA1c in this group.
Location NSW, SA, VIC, WA
Age 12-25 years
Using an insulin pump already
Having your past 2 HbA1c readings above 9%
Become a game changer.
Get the latest research updates straight to your inbox and be the first to hear about new clinical trials.